Who is sponsoring NCT05616533?

NCT05616533 is sponsored by Zhejiang University.

What drugs are being tested in NCT05616533?

Interventions in NCT05616533: biopsy of tumor before treatment.

What condition does NCT05616533 study?

NCT05616533 studies Precise Prediction of Therapy Efficiency.

Is NCT05616533 still recruiting?

NCT05616533 is currently status unknown. Last updated 26 December 2023.

Last reviewed 2023-12-26 · How we verify

NCT05616533

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Consistency of PDX Model for Predicting Therapeutic Effect of Gastric Cancer

Status unknown Last updated 26 December 2023

What this trial tests

trial testing biopsy of tumor before treatment in Precise Prediction of Therapy Efficiency in 50 participants. Status unknown.

Timeline

12 September 2023

Primary endpoint
30 September 2024

30 June 2025

Quick facts

Lead sponsor	Zhejiang University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	12 September 2023
Primary completion	30 September 2024
Estimated completion	30 June 2025
Sites	1 location across China

Drugs / interventions tested

biopsy of tumor before treatment

Conditions studied

Precise Prediction of Therapy Efficiency — all drugs for Precise Prediction of Therapy Efficiency →

Sponsor

Zhejiang University

Who can join

Adults 18 to 75, any sex, with Precise Prediction of Therapy Efficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to compare the tumor response in gastric cancer patients given neoadjuvant chemotherapy with the corresponding result obtained from zebrafish patient-derived tumor xenograft(PDX) model given the same regimen. The main question it aims to answer is whether this PDX model of zebrafish could accurately predict the effect of chemotherapy in advanced gastric cancer. Participants will be given the standard neoadjuvant treatment administrated by their own doctors and tumor response will be observed and recorded. Meanwhile, tumor samples derived from patients before chemotherapy will be transplanted to zebrafish and the same regimen will be given to the PDX models correspondingly. The tumor response data both from clinical practice and PDX model platform will be analysed and compared to evaluate the power of this zebrafish model platform in drug efficiency prediction.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Patient-derived xenograft models in cancer therapy: technologies and applications.
Liu Y, Wu W, Cai C, Zhang H, et al · · 2023 · cited 290× · PMID 37045827 · DOI 10.1038/s41392-023-01419-2
Development of an orthotopic medulloblastoma zebrafish model for rapid drug testing.
van Bree N, Oppelt AS, Lindström S, Zhou L, et al · · 2025 · cited 7× · PMID 39383211 · DOI 10.1093/neuonc/noae210
Zebrafish as a Model for Translational Immuno-Oncology.
Barbosa GR, de Souza AM, Silva PF, Fávero CS, et al · · 2025 · cited 1× · PMID 40710421 · DOI 10.3390/jpm15070304
What value do zebrafish have to anticancer drug discovery?
Xiao B, Landesman-Bollag E, Feng H. · · 2024 · cited 1× · PMID 38327017 · DOI 10.1080/17460441.2024.2313454

Verify or expand the search:

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05616533 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 26 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05616533.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing